IIM - Epidemiology Rare, estimated annual incidence 5-10/million, estimated prevalence ~ 60/million. PM and DM peak in prevalence in childhood (5- 15yrs)

Slides:



Advertisements
Similar presentations
Chronic Disease and Co-morbidity with Hearing Loss
Advertisements

Lupus in Pregnancy Darren Farley, MD Clinical Assistant Professor
Virginia Steen, MD Professor of Medicine
DR SANTOSH KUMAR ASSISTANT PROFESSOR MEDICINE UNTI 2.
Juvenile Rheumatoid Arthritis B. Paul Choate, M.D.
Dyspnea and Rash Andres Quiceno, MD Rheumatology PHD.
Plain Films Radiographs PA and Lateral Views CT Chest.
Autoantibodies in PM and DM Autoantibodies:>90% Autoantibodies:>90% Positive ANA:60-80% Positive ANA:60-80%  More in overlap  Low in IBM Defined antibodies:50%
Autoimmune Diseases Dr. Raid Jastania. Autoimmune Diseases Group of diseases with common pathological process Presence of auto-antibody ?defect in B-cells.
1 Serum Enzymes in Disease Dr. Essam H. Aljiffri.
Valvular Heart Disease Dr. Raid Jastania. Valvular Heart Disease Congenital or Acquired Part of congenital heart diseases May involve any valve: Aortic,
All About Rheumatoid Arthritis
DIAGNOSIS of AUTOIMMUNE DISEASES Assos. Prof. Gülderen Yanıkkaya Demirel MD, PhD Yeditepe University School of Medicine Immunology Department, Medical.
Lecture 5. Infarction The process by which necrosis results from ischemia is called infarction Ischemic necrosis of myocardial cells is one of the commonest.
Systemic Lupus Erythematosus (SLE) Cheryl McConnell RN, MSN.
Idiopathic Inflammatory Myopathies
WEGENER’S GRANULOMATOSIS
INFLAMMATORY MYOPTHIES
Rheumatoid Arthritis(RA)
GASTRIC LYMPHOMAS Aswad H. Al.Obeidy FICMS, FICMS GE&Hep Kirkuk General Hospital.
Morning Report 7/13/09.  Acute febrile vasculitic syndrome of early childhood  Affecting all blood vessels in the body but mostly medium and small vessels.
Dr. M. A. SOFI MD; FRCP; (London); FRCPEdin;FRCSEdin.
Esam H. Alhamad, M.D Assistant Professor of Medicine Consultant Pulmonary & Critical Care Medicine.
Cirrhosis Dr. Meg-angela Christi M. Amores. Cirrhosis a histopathologically defined condition – pathologic features consist of the development of fibrosis.
September 24,  20% diagnosed in childhood  Mostly in adolescence  F:M ratio  Prior to puberty - 3:1  After puberty - 9:1  Native Americans.
Copyright © 2008 Delmar Learning. All rights reserved. Unit 6 Classification of Disease.
Department of Neurology, The 2nd affiliated hospital, kunming Medical College Yinfengqiong.
Case Discussion Dr. Raid Jastania. What is the outcome of inflammation?
Katie DePlatchett, M.D. AM Report May 26, 2010 Inflammatory Myopathies.
Yuliarni Syafrita Bagian Neurolog FK Unand
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
Biochemical markers for diagnosis of diseases and follow up Dr. Rana Hasanato Associate professor and consultant Head of clinical chemistry department.
Idiopathic Inflammatory Myopathies. The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of disorders characterized by symmetric proximal.
Biochemical markers for diagnosis and follow up of disease
CLINICAL MANIFESTATION OF SYSTEMIC SCLEROSIS
INFLAMMATORY MYOPTHIES
Mixed Connective Tissue Disease
Rheumatic Fever Dr.Emamzadegan Pediatric Cardiologist.
Tuberculosis in Children and Young Adults
Sarra Abdurrezag Esharik Systemic Lupus Erythematosus (SLE)
Please enjoy the show…….. By : Ashlee Kolkow What is RA? Most serious form of arthritis, leading to severe crippling Autoimmune disorder Chronic inflammation.
Thyroid disorders. Diseases of the thyroid predominantly affect females and are common, occurring in about 5% of the population.
Introduction to Pathophysiology J. Joachim Hightower High School
Idiopathic Inflammatory Myopathies; how significant is creatine kinase levels in diagnosis and prognosis? Case report and literature review Travis Sizemore.
DEVELOPED IN PART BY THE COMMUNITY WELLNESS TEAM Diabetes GETTING STARTED.
Systemic Lupus Erythematosus (SLE). SLE Lupus is the latin word for “WOLF” Is an autoimmune disorder characterized by inflammation of almost any body.
Dr. Ashwin Kulkarni M.S.Ramaiah Medicial College Bangalore India
Scleroderma.
MYOSITIS (Infammatory Myopathies)
Sjogren’s syndrome.
Biochemical Investigations In Heart Disaeses
A New Anti-inflammatory Therapy For COPD
Internist, Rheumatologist
Systemic Lupus Erythematosis
Henoch–Schönlein Purpura (HEN-awk SHURN-line PUR-pu-ruh)
Dr Chandrashekara S Medical Director
Autoimmune diseases Ali Al Khader, M.D. Faculty of Medicine
INFLAMMATORY MYOPTHIES
School of Allied Health & College of Applied Sciences and Arts
Idiopathic Inflammatory Myopathies
Sytemic Lupus Erythematosus
Dermatomyositis perifascicular pattern of involvement
NP D.P. Bx: 9/8/2017.
Cardiac enzymes and cardiac proteins
Inflammatory myopathies
MDA-5 Dermatomyositis: An Atypical Variant
Case Study 83 Leonidas Arvanitis, MD
Biochemical markers for diagnosis of diseases and follow up
Dermatomyositis and polymyositis
Presentation transcript:

IIM - Epidemiology Rare, estimated annual incidence 5-10/million, estimated prevalence ~ 60/million. PM and DM peak in prevalence in childhood (5- 15yrs) and mid-life (30-50yrs); IBM peaks after age 50. Females are preferentially affected (~2-3:1) in all forms except in IBM (female:male~1:3).

IIM - Epidemiology African-Americans may be at increased risk for IIM and poorer outcomes compared to Caucasians. All races on all continents are affected. Anecdotal clustering of IIM onset in time and space suggest strong environmental influences.

IIM – Systemic manifestations General manifestations:fatigue, fever, weight loss. Musculoskeletal: myalgia, muscle tenderness and weakness. Arthralgia, arthritis, contractures. Dermatologic:Photosensitive rashes and edema. Vasculitis with infarcts and ulceration. Subcutaneous inflammation (panniculitis) and calcification.

IIM – Systemic manifestations Gastrointestinal: oropharyngeal involvement with tongue weakness and voice changes; dysphagia and reflux. Pulmonary:Atelectasis, cough. Interstitial lung disease. Aspiration. Cardiovascular:Tachyrhythmias and other conduction abnormalities. Congestive heart failure from myocarditis or cor pulmonale. Raynaud.

IIM - Evaluation Careful history and physical examination to define: 1.The time\tempo of symptom onset and progression. 2.The exact nature of the problems and associated factors. 3.Medical and family history. 4.Muscle bulk/strength, rashes, cardiac, pulmonary, GI findings. 5.Environmental exposures temporally associated.

IIM - Evaluation Laboratory evaluation directed by the above: 1.Muscle enzymes, serologies, tests to R/O other diseases. 2.Radiographic studies, muscle MRI. 3.EMG, biopsies of skin, muscle, possibly other tissues. 4.Special serologic or genetic studies depending upon results from the above.

IIM – Laboratory abnormalities Sarcoplasmic enzymes (CPK, LDH, ALT, AST, aldolase) – useful in assessing myositis activity. CPK MB fraction – correlates with diseases activity and is not usually indicative of cardiac involvement unless the ratio of CK-MB/total CK rapidly increases. ESR/CRP – elevated in <30% of pts. ANA – positive in 60-90% of pts; best single lab discriminator of IIM from other myopathies.

Causes of elevated serum CPK enzyme activity Physical trauma or muscle stress. 1.Any muscle trauma – falls, EMG studies, surgery, muscle bipsy, IM injection. 2.Strenuous, prolonged exercise-marathon running, forced marching. Drug effects 1.On muscle itself – clofibrate, ethanol, amphetamines, heroin. 2.On CK metabolism/clearance-phenobarbital, morphine, diazepam.

Causes of elevated serum CPK enzyme activity Diseases 1.Directly affecting muscle-non inflammatory myopathies of all kinds, MI, malignant hyperthermia, infectious myopathies, IIM. 2.Affecting blood supply to muscle-emboli to muscle, vasculitis,prolonged immobilization. 3.Affecting the CNS-cerebral ischemia, trauma,infections. Possible familial cases in African-Americans.

Myositis –specific autoantibodies (MSA) 1.Anti-synthetases – Jo 1(anti histidyl tRNA synthetase). 2.Anti-signal recognition particle (SRP). 3.Anti-Mi-2. They are directed at conserved conformational epitopes on phosphorylated, cytoplasmic ribonucleoprotein particles involved in translation and present in all cells.

MSA They inhibit the function of the protein they target. They appear to arise months prior to myositis onset, are antigen driven, vary in titer with myositis disease activity and occasionally become negative after prolonged remission.

Associations of the MSA Anti-synthetases (Jo1): Arthritis, interstitial lung disease, fevers, mechanic’s hand, Raynaud’s. Acute onset, severe disease. Moderate response to therapy. Prognosis poor; 70% 5-yrs survival. Frequency in IIM 25-30%.

Associations of the MSA Anti-SRP: Cardiac involvement, myalgias, mostly in black females. Very acute onset, very severe disease. Poor response to therapy. Poor prognosis – 25% 5 yrs survival. Frequency in IIM – 5%.

Associations of the MSA Anti-Mi-2: Classic dermatomyositis. Acute onset. Mild disease. Good response to therapy Good prognosis. Nearly 100% 5 yrs survival/ Frequency in IIM 5-10%.

IIM - pathogenesis Polymyositis and inclusion body myositis may be more cellularly mediated (CD8+ T cells). Dermatomyositis may be more humorally mediated (B cells).

IIM – Activity evaluation 1.Muscle strength – grading: 5 – normal power resistance. 4 – power decreased but muscle contraction possible against resistance. 3 – muscle contraction against gravity only. 2 – muscle contraction possible only when gravity is eliminated. 1 – contraction without motion. 0 – no contraction.

IIM – Activity evaluation 2. CPK levels. 3.EMG: fibrillations, positive sharp waves, short small polyphasic motor units, high frequency repetitive discharges, normal nerve conduction velocities. 4.Muscle biopsy: myofiber degeneration/regenaration, MNC infiltrates, perifascicular atrophy.

IIM – Activity evaluation 4.MRI: T1-weighted images – chronic changes in muscles, atrophy. T2 – weighted and STIR images – active inflammation. Biopsy is taken from a weak muscle, without atrophy, not damaged by EMG, injection, etc.

Poor prognostic factors in Myositis Based on demographic features: 1.Age : older. 2.Gender: female. 3.Race: black. Based on signs-symptoms: 1.Fever, dysphagia, severe myositis. 2.Cardiac, pulmonary or GI involvement. 3.Delay to diagnosis and treatment. 4.Failure to induce remissin.

Poor prognostic factors in Myositis Based on clinical or serologic group: 1.Clinical groups: polymyositis, cancer-associated or inclusion body myositis. 2.Serologic groups: anti-synthetases or anti-SRP autoantibodies.

Therapy Steroids 1-2mg/kg/d. Cytotoxic: MTX, AZT, cytoxan IVIG Plaquenil (rash). Rehabilitation and physical therapy.